68 - Respiratory Syncytial Virus Vaccine is Associated With Better Outcomes in Inflammatory Bowel Disease Patients over 60 Years Old: A US Propensity-Matched Study

Award: ACG Outstanding Research Award in the IBD Category (Trainee)

Osama Hamid, MD¹, Shaikhoon S. Mohammed, MD², Mohanad Awadalla, MD³, Faris Hammad, MD⁴, Miguel D Regueiro, MD^5
1University of Texas Southwestern Medical Center, Dallas, TX; ²Emory Clinic/Emory Healthcare, Atlanta, GA; ³Beth Israel Deaconess Medical Center, Boston, MA; ⁴Cleveland Clinic Foundation, Westlake, OH; ⁵Cleveland Clinic, Cleveland, OH

Introduction: The Respiratory Syncytial Virus (RSV) vaccine was approved by the FDA in May 2023 for adults aged over 60. Recent literature indicates that adult IBD patients face more than a 2-fold increased risk of RSV compared to the general population. Our objective is to assess the effects of the RSV vaccine in IBD population aged over 60.

Methods: We conducted a retrospective cohort study utilizing a large database (TriNetX), which aggregates over 100 million unique patients’ charts. We identified adults ( >60 years old) diagnosed with IBD and divided into 2 groups: patients who received RSV vaccine (study), and those who did not receive RSV vaccine (control), in the duration from June 2023 to May 2024. We performed 1:1 propensity-score matching (PSM) for demographics, comorbidities, common pneumonia risk factors, malignancy, anti-neoplastic agents and IBD medications. The primary outcomes were the risk of RSV pneumonia, acute respiratory failure (ARF), hospital inpatient admission and critical care services (ICU), occurring 30 days or more after the vaccine administered. Odds ratios (OR) with 95% confidence intervals (CI) were calculated to express the risk of each variable. A p-value of < 0.05 was considered statistically significant.

Results: A total of 452 patients were identified in the study group and 243,695 patients in control. The demographic profile, comorbidities and medications are detailed in Table 1. After PSM, 439 patients were included in each group. The vaccinated group had a lower risk of RSV pneumonia (OR 0.21 95% CI [0.10-0.43]), ARF (OR 0.42 95% CI [0.19-0.90]), hospital inpatient admission (OR 0.46 95% CI [0.21-0.93]), and ICU services (OR 0.28 95% CI [0.14-0.59]), compared to the unvaccinated group, Figure 1.

Discussion: This large database analysis revealed a lower RSV pneumonia risk and better health outcomes associated with RSV vaccination in IBD patients over 60 years. It is recommended that older IBD patients receive RSV vaccine. To date, the RSV vaccine does not exacerbate IBD.




Disclosures:


Osama Hamid, MD¹, Shaikhoon S. Mohammed, MD², Mohanad Awadalla, MD³, Faris Hammad, MD⁴, Miguel D Regueiro, MD⁵, 68, Respiratory Syncytial Virus Vaccine is Associated With Better Outcomes in Inflammatory Bowel Disease Patients over 60 Years Old: A US Propensity-Matched Study, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.